See the lifestyle promoted by Caldwell Esselstyn. Patients in his studies who stayed with it never had a cardiovascular event again. Despite all of them basically having multiple failed bypass surgeries prior and being told to basically go home and die.

Thank you for this question! We appreciate your interest in our research and work to ensure widespread access to therapies that cure and prevent the diseases and disabilities of aging. Please stay tuned for the answer to your question, coming to our SENSible Q blog later this year by visiting www.sens.org/blog/ and subscribing to our newsletter at www.sens.org/subscribe/

When the trial is launched, Cyclarity will certainly announce it; check back periodically on their news page: cyclaritytx.com/news-publications/ ... and if you use them, follow them on the various social media platforms: www.linkedin.com/company/30597796/ facebook.com/Underdog-Pharmaceuticals-106943334091737/ twitter.com/UnderdogPharma

Not directly, but it could still have an impact on the disease. The central intracellular waste driving macular degeneration is a compound related to vitamin A called A2E. Cyclarity's modified cyclodestrin is very unlikely to sequester A2E, but there's evidence that 7KC (which is the target of their modified cyclodextrin) does have a role in the disease process. So it might be useful as a treatment to help slow the disease down, or might also delay the onset in otherwise-healthy aging people - especially those at high risk. Answering those questions will be some time down the road: for now, the focus is on atherosclerotic cardiovascular disease, the number one killer in the world.